An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
Identifieur interne : 000A75 ( PubMed/Checkpoint ); précédent : 000A74; suivant : 000A76An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
Auteurs : Christopher B. Fox [États-Unis] ; Jean HaenslerSource :
- Expert review of vaccines [ 1744-8395 ] ; 2013.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (), Adjuvants immunologiques (administration et posologie), Adjuvants immunologiques (effets indésirables), Adjuvants immunologiques (histoire), Association médicamenteuse, Essais cliniques comme sujet, Histoire du 20ème siècle, Histoire du 21ème siècle, Humains, Polysorbates (), Polysorbates (administration et posologie), Polysorbates (effets indésirables), Polysorbates (histoire), Squalène (), Squalène (administration et posologie), Squalène (effets indésirables), Squalène (histoire), Surveillance post-commercialisation des produits de santé, Vaccins (administration et posologie), Vaccins (effets indésirables), Vaccins (immunologie), alpha-Tocophérol (), alpha-Tocophérol (administration et posologie), alpha-Tocophérol (effets indésirables), alpha-Tocophérol (histoire), Émulsions (), Émulsions (administration et posologie), Émulsions (effets indésirables), Émulsions (histoire).
- MESH :
- administration et posologie : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins, alpha-Tocophérol, Émulsions.
- effets indésirables : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins, alpha-Tocophérol, Émulsions.
- histoire : Adjuvants immunologiques, Polysorbates, Squalène, alpha-Tocophérol, Émulsions.
- immunologie : Vaccins.
- Adjuvants immunologiques, Association médicamenteuse, Essais cliniques comme sujet, Histoire du 20ème siècle, Histoire du 21ème siècle, Humains, Polysorbates, Squalène, Surveillance post-commercialisation des produits de santé, alpha-Tocophérol, Émulsions.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (adverse effects), Adjuvants, Immunologic (chemistry), Adjuvants, Immunologic (history), Clinical Trials as Topic, Drug Combinations, Emulsions (administration & dosage), Emulsions (adverse effects), Emulsions (chemistry), Emulsions (history), History, 20th Century, History, 21st Century, Humans, Polysorbates (administration & dosage), Polysorbates (adverse effects), Polysorbates (chemistry), Polysorbates (history), Product Surveillance, Postmarketing, Squalene (administration & dosage), Squalene (adverse effects), Squalene (chemistry), Squalene (history), Vaccines (administration & dosage), Vaccines (adverse effects), Vaccines (immunology), alpha-Tocopherol (administration & dosage), alpha-Tocopherol (adverse effects), alpha-Tocopherol (chemistry), alpha-Tocopherol (history).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Emulsions, Polysorbates, Squalene, Vaccines, alpha-Tocopherol.
- chemical , adverse effects : Adjuvants, Immunologic, Emulsions, Polysorbates, Squalene, Vaccines, alpha-Tocopherol.
- chemical , chemistry : Adjuvants, Immunologic, Emulsions, Polysorbates, Squalene, alpha-Tocopherol.
- chemical , history : Adjuvants, Immunologic, Emulsions, Polysorbates, Squalene, alpha-Tocopherol.
- chemical , immunology : Vaccines.
- Clinical Trials as Topic, Drug Combinations, History, 20th Century, History, 21st Century, Humans, Product Surveillance, Postmarketing.
Abstract
With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In this review, the authors introduce emulsion adjuvant composition and history before detailing the most recent findings from clinical and postmarketing data regarding the effects of emulsion adjuvants on vaccine immunogenicity and safety, with emphasis on the most widely distributed emulsion adjuvants, MF59® and AS03. The authors also present a summary of other emulsion adjuvants in clinical development and indicate promising avenues for future emulsion-based adjuvant development. Overall, emulsion adjuvants have demonstrated potent adjuvant activity across a number of disease indications along with acceptable safety profiles.
DOI: 10.1586/14760584.2013.811188
PubMed: 23885820
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23885820Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.</title><author><name sortKey="Fox, Christopher B" sort="Fox, Christopher B" uniqKey="Fox C" first="Christopher B" last="Fox">Christopher B. Fox</name><affiliation wicri:level="2"><nlm:affiliation>IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102, USA. cfox@idri.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Haensler, Jean" sort="Haensler, Jean" uniqKey="Haensler J" first="Jean" last="Haensler">Jean Haensler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23885820</idno><idno type="pmid">23885820</idno><idno type="doi">10.1586/14760584.2013.811188</idno><idno type="wicri:Area/PubMed/Corpus">000978</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000978</idno><idno type="wicri:Area/PubMed/Curation">000978</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000978</idno><idno type="wicri:Area/PubMed/Checkpoint">000A75</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.</title><author><name sortKey="Fox, Christopher B" sort="Fox, Christopher B" uniqKey="Fox C" first="Christopher B" last="Fox">Christopher B. Fox</name><affiliation wicri:level="2"><nlm:affiliation>IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102, USA. cfox@idri.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Haensler, Jean" sort="Haensler, Jean" uniqKey="Haensler J" first="Jean" last="Haensler">Jean Haensler</name></author></analytic><series><title level="j">Expert review of vaccines</title><idno type="eISSN">1744-8395</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adjuvants, Immunologic (adverse effects)</term><term>Adjuvants, Immunologic (chemistry)</term><term>Adjuvants, Immunologic (history)</term><term>Clinical Trials as Topic</term><term>Drug Combinations</term><term>Emulsions (administration & dosage)</term><term>Emulsions (adverse effects)</term><term>Emulsions (chemistry)</term><term>Emulsions (history)</term><term>History, 20th Century</term><term>History, 21st Century</term><term>Humans</term><term>Polysorbates (administration & dosage)</term><term>Polysorbates (adverse effects)</term><term>Polysorbates (chemistry)</term><term>Polysorbates (history)</term><term>Product Surveillance, Postmarketing</term><term>Squalene (administration & dosage)</term><term>Squalene (adverse effects)</term><term>Squalene (chemistry)</term><term>Squalene (history)</term><term>Vaccines (administration & dosage)</term><term>Vaccines (adverse effects)</term><term>Vaccines (immunology)</term><term>alpha-Tocopherol (administration & dosage)</term><term>alpha-Tocopherol (adverse effects)</term><term>alpha-Tocopherol (chemistry)</term><term>alpha-Tocopherol (history)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques ()</term><term>Adjuvants immunologiques (administration et posologie)</term><term>Adjuvants immunologiques (effets indésirables)</term><term>Adjuvants immunologiques (histoire)</term><term>Association médicamenteuse</term><term>Essais cliniques comme sujet</term><term>Histoire du 20ème siècle</term><term>Histoire du 21ème siècle</term><term>Humains</term><term>Polysorbates ()</term><term>Polysorbates (administration et posologie)</term><term>Polysorbates (effets indésirables)</term><term>Polysorbates (histoire)</term><term>Squalène ()</term><term>Squalène (administration et posologie)</term><term>Squalène (effets indésirables)</term><term>Squalène (histoire)</term><term>Surveillance post-commercialisation des produits de santé</term><term>Vaccins (administration et posologie)</term><term>Vaccins (effets indésirables)</term><term>Vaccins (immunologie)</term><term>alpha-Tocophérol ()</term><term>alpha-Tocophérol (administration et posologie)</term><term>alpha-Tocophérol (effets indésirables)</term><term>alpha-Tocophérol (histoire)</term><term>Émulsions ()</term><term>Émulsions (administration et posologie)</term><term>Émulsions (effets indésirables)</term><term>Émulsions (histoire)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Emulsions</term><term>Polysorbates</term><term>Squalene</term><term>Vaccines</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Emulsions</term><term>Polysorbates</term><term>Squalene</term><term>Vaccines</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Emulsions</term><term>Polysorbates</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="history" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Emulsions</term><term>Polysorbates</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>Vaccins</term><term>alpha-Tocophérol</term><term>Émulsions</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>Vaccins</term><term>alpha-Tocophérol</term><term>Émulsions</term></keywords><keywords scheme="MESH" qualifier="histoire" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>alpha-Tocophérol</term><term>Émulsions</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Drug Combinations</term><term>History, 20th Century</term><term>History, 21st Century</term><term>Humans</term><term>Product Surveillance, Postmarketing</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Association médicamenteuse</term><term>Essais cliniques comme sujet</term><term>Histoire du 20ème siècle</term><term>Histoire du 21ème siècle</term><term>Humains</term><term>Polysorbates</term><term>Squalène</term><term>Surveillance post-commercialisation des produits de santé</term><term>alpha-Tocophérol</term><term>Émulsions</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In this review, the authors introduce emulsion adjuvant composition and history before detailing the most recent findings from clinical and postmarketing data regarding the effects of emulsion adjuvants on vaccine immunogenicity and safety, with emphasis on the most widely distributed emulsion adjuvants, MF59® and AS03. The authors also present a summary of other emulsion adjuvants in clinical development and indicate promising avenues for future emulsion-based adjuvant development. Overall, emulsion adjuvants have demonstrated potent adjuvant activity across a number of disease indications along with acceptable safety profiles. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23885820</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.</ArticleTitle><Pagination><MedlinePgn>747-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/14760584.2013.811188</ELocationID><Abstract><AbstractText>With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In this review, the authors introduce emulsion adjuvant composition and history before detailing the most recent findings from clinical and postmarketing data regarding the effects of emulsion adjuvants on vaccine immunogenicity and safety, with emphasis on the most widely distributed emulsion adjuvants, MF59® and AS03. The authors also present a summary of other emulsion adjuvants in clinical development and indicate promising avenues for future emulsion-based adjuvant development. Overall, emulsion adjuvants have demonstrated potent adjuvant activity across a number of disease indications along with acceptable safety profiles. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102, USA. cfox@idri.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haensler</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C550253">ASO3B adjuvant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004655">Emulsions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical><Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber><NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004655" MajorTopicYN="N">Emulsions</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23885820</ArticleId><ArticleId IdType="doi">10.1586/14760584.2013.811188</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Washington (État)</li></region></list><tree><noCountry><name sortKey="Haensler, Jean" sort="Haensler, Jean" uniqKey="Haensler J" first="Jean" last="Haensler">Jean Haensler</name></noCountry><country name="États-Unis"><region name="Washington (État)"><name sortKey="Fox, Christopher B" sort="Fox, Christopher B" uniqKey="Fox C" first="Christopher B" last="Fox">Christopher B. Fox</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000A75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23885820
|texte= An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23885820" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |